Expert Calls for Shorter Radiation Use in Prostate Cancer Treatment


“Men with prostate cancer can receive shorter courses of radiation therapy than what is currently considered standard, according to Justin Bekelman, MD, an associate professor of Radiation Oncology, Medical Ethics, and Health Policy at the University of Pennsylvania’s Perelman School of Medicine and Abramson Cancer Center. In his call for practice change, Bekelman cites research showing the shorter radiation treatment — known as moderate hypofractionation — is just as effective at treating cancer, while costing less and easing the burden on patients. The commentary was published online by the International Journal of Radiation Oncology Biology and Physics and was co-authored by W. Robert Lee, MD, MEd, MS, a professor of Radiation Oncology at the Duke University School of Medicine.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.

Hypofractionation May Be Poised to Become New Standard of Care for Prostate Cancer


“There has been an ongoing debate about which type of radiation therapy is preferable in the treatment of localized prostate cancer: hypofractionation (larger fractions given over 4–5 weeks) or conventional radiotherapy (given over 8–9 weeks). A new study presented at the 2016 ASCO Annual Meeting may help to resolve that debate.

“The large, randomized trial found that hypofractionation was not inferior to conventional radiation therapy in terms of efficacy or safety in men with localized intermediate-risk prostate cancer. This is the third large, randomized, contemporary study to demonstrate that both techniques have equivalent efficacy and safety.”

Go to full article.

Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.

HYPRO: Shorter RT Course No Better, Worse in Localized Prostate Cancer


“A randomized phase III trial found that a hypofractionated radiotherapy (RT) regimen was not superior to, but generally equivalent to a conventional RT scheme in men with localized prostate cancer. The study joins a growing body of literature on hypofractionation in this malignancy, generally showing that the shorter courses are a reasonable option.

“A low α-β ratio for prostate cancer has generated interest in hypofractionation, as it could increase the tumor dose without increasing toxicities. ‘Moreover, hypofractionated radiotherapy is delivered in fewer fractions, improving patients’ convenience, hospital logistics, and possibly reducing healthcare costs,’ wrote study authors led by Luca Incrocci, MD, PhD, of Erasmus Medical Center Cancer Institute in Rotterdam, the Netherlands.

“A study was presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago that found a hypofractionated regimen of 60 Gy in 20 fractions was noninferior to conventional RT. Another, presented this past January at the ASCO Genitourinary Cancers Symposium, again found a 60 Gy/20 fractions regimen was noninferior to conventional RT and to another hypofractionated regimen of 57 Gy/19 fractions.”

Go to full article.

Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.

Shorter-Course Radiation Non-Inferior to Conventional Therapy for Low-Risk Prostate Cancer

“Hypofractionated radiation therapy yielded a similar rate of DFS and toxicity profile as conventional radiotherapy among men with low-risk prostate cancer, according to results of a randomized phase 3 non-inferiority study presented at the ASTRO Annual Meeting.

“Given in larger doses over a shorter period, hypofractionated radiation therapy is being studied as a possible improved treatment option for some patients.

“Howard Sandler, MD, MS, FASTRO, professor and chair of the department of radiation oncology at Cedars Sinai Medical Center in New York, and colleagues sought to evaluate whether the hypofractionated therapy schedule — or 70 Gy in 28 fractions over 5.6 weeks — resulted in a 5-year DFS that was not lower than that of the conventional schedule, or 73.8 Gy in 41 fractions over 8.2 weeks, by more than 7%.”

Prostate Cancer Study Shows Hypofractionation Comparable to Standard Radiation in Low-risk Patients

“Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to follow-up RTOG 0415 study data presented October 20, 2015, during a scientific session at the 2015 ASTRO Annual Meeting.

“Hypofractionated radiotherapy is delivered in larger doses over 5.5 weeks whereas conventional radiotherapy requires 8 weeks of treatment. ‘Results of our study demonstrate that for men with low-risk prostate cancer, hypofractionated radiotherapy offers a shorter, more convenient treatment schedule without compromising cure or causing additional side effects,’ said lead author W. Robert Lee, MD, professor of radiation oncology at Duke University School of Medicine, Durham, NC.”

Hypofractionation of Breast Radiotherapy Associated With Reduced Acute Toxicity

“In an analysis reported in JAMA Oncology, Jagsi et al found that hypofractionation of whole-breast radiotherapy was associated with reduced acute toxicity compared with conventional fractionation.

“The study involved data on physician-assessed toxic effects and patient-reported outcomes in 2,309 patients who received adjuvant whole-breast radiotherapy after lumpectomy for unilateral breast cancer at Michigan Radiation Oncology Quality Consortium sites from October 2011 through June 2014. Patients had to have a comprehensive physician toxicity evaluation within 1 week of completing radiotherapy and at least 1 weekly evaluation during treatment.”

Shorter, Cheaper Radiation Treatment Not given to Most Breast Cancer Patients

“In 2011, expert guidelines endorsed shorter whole breast radiation for early-stage breast cancer patients. However, a new study finds that this less costly treatment has not reached many patients who meet guidelines to receive it.

“The study – led by Dr. Justin E. Bekelman, of the University of Pennsylvania Perelman School of Medicine in Philadelphia – is published in JAMA and is released to coincide with the San Antonio Breast Cancer Symposium.

“The researchers explain that breast conservation therapy is the most common treatment for early-stage breast cancer, with whole breast irradiation (WBI) recommended for most women after surgery, as it reduces recurrence and improves overall survival.

“Conventional WBI has been the ‘mainstay’ of treatment in the US and consists of 5-7 weeks of daily radiation treatments. However, hypofractionated WBI is a shorter alternative to conventional WBI, consisting of fewer higher-dose treatments over 3 weeks.

” ‘Hypofractionated WBI increases convenience, reduces treatment burden and lowers health care costs,’ note the authors, ‘while offering similar cancer control and cosmesis (cosmetic outcomes) to conventional WBI.’ They also note that patients naturally prefer shorter radiation treatments.”

Prostate Cancer Patients who Receive Hypofractionated Radiation Therapy Report Consistent Quality of Life Before and After Treatment

The gist: This article covers the results of a clinical trial—a research study with volunteer patients. The trial explored the effects on quality of life of a type of a prostate cancer treatment called hypofractionated (HPFX) radiation therapy. HPRX radiation therapy is different from standard radiation treatment in that “the total dose of radiation is divided into large doses and administered over a shorter period of time (fewer days or weeks).” Patients who participated in the clinical trial reported that their quality of life after HPFX treatment was similar to their quality of life before their treatment. The promising results mean that further studies will continue to explore HPFX as a possible standard treatment for some prostate cancer patients.

“Prostate cancer patients who received hypofractionated (HPFX) radiation therapy (RT) reported that their quality of life, as well as bladder and bowel function were at similar levels before and after RT, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting. Additionally, results indicate that parallel quality of life outcomes occurred between groups of patients who receive different regimens of HPFX RT.

“The phase I/II trial enrolled 343 patients with low-to-intermediate risk prostate cancer at five institutions from 2002 to 2010 to study the effectiveness of HPFX RT, as well as the patients’ ability to tolerate the treatment. HPFX RT is radiation therapy in which the total dose of radiation is divided into large doses and administered over a shorter period of time (fewer days or weeks) than standard RT.

“All of the patients received intensity-modulated radiation therapy (IMRT) to the prostate and base of the seminal vesicles. IMRT is an advanced high-precision RT that uses guided imaging techniques to deliver well-defined radiation doses to a tumor or specific areas within the tumor. IMRT allows for the radiation dose to conform more precisely to the three-dimensional shape of a tumor while minimizing radiation to surrounding tissues.

“Patients were divided into three groups based on dose-per-fraction schedules (the amount of radiation administered during each RT session). Researchers calculated and designed the three different HPFX regimens in hopes that each might achieve similar disease control and consistently minimal side effects for patients. Group One’s HPFX levels were 64.7 Gy total, with 22 fractions (doses) of 2.94 Gy each. Group Two’s HPFX levels were 58.08 Gy total, with 16 fractions (doses) of 3.63 Gy each. Group Three’s HPFX levels were 51.6 Gy total with 12 fractions (doses) of 4.3 Gy each.”